Treatment of ocular signs and symptoms of seasonal allergic conjunctivitis.
Composition:
1 ml of solution contains 1 mg olopatadine (as hydrochloride). The preparation contains benzalkonium chloride.
Action:
A strong and selective antiallergic / antihistamine drug. Olopatadine antagonizes the action of histamine and prevents the histamine-induced production of cytokines by human conjunctival epithelial cells. Data from testsin vitro they suggest that it can affect the human conjunctival mast cells by inhibiting the production of inflammatory mediators. It has been suggested that patients with patent nasal-lacrimal tract administration of olopatadine to the eye reduce the severity of the subjective and subjective symptoms of the nose, which often coexist with seasonal allergic conjunctivitis. Olopatadine does not cause clinically significant changes in pupil diameter.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients.
Precautions:
If symptoms of serious adverse reactions or hypersensitivity occur, the drug should be discontinued. The benzalkonium chloride contained in the preparation may cause punctate and / or toxic ulcerative corneal defects; careful monitoring of patients who frequently or prolonged use of the preparation and who have dry eye or diseases in which corneal function is impaired is required. Do not instill the product while wearing contact lenses. Wait 10-15 minutes after instillation of the preparation for contact lenses.
Pregnancy and lactation:
Caution should be exercised when prescribing to pregnant women. The use of olopatadine by breast-feeding mothers is not recommended.
Side effects:
Common: headaches, disturbed taste, eye pain, eye irritation, dry eye, unusual sensations in the eyes, dry nose, tiredness. Uncommon: rhinitis, dizziness, decreased sensation of the touch, corneal erosion, corneal epithelium abnormalities, corneal epithelial disorder, corneal keratitis, keratitis, corneal spots, eye discharge, photophobia, blurred vision, reduced visual acuity, blepharospasm eye discomfort, ocular pruritus, conjunctival bumps, conjunctivitis, feeling of foreign body presence in eyes, increased tearing, eyelid pruritus, eyelid flushing, eyelid edema, eyelid disease, conjunctival congestion, ocular congestion, contact dermatitis, skin burning sensation , dry skin. After placing on the market (frequency unknown): corneal edema, conjunctivitis, swelling of the eye, swollen eye, mydriasis, blurred vision, scabbing on the eyelids, hypersensitivity, shortness of breath, drowsiness, facial edema, dermatitis, erythema, nausea, vomiting, sinusitis, muscle weakness, malaise.
Dosage:
1 drop into the conjunctival sac of the affected eye (eyes) twice a day (with a gap of 8 hours between instillations). If necessary, treatment can be continued for up to 4 months. For concomitant treatment with other topical ophthalmic medications, a 5-10 minute interval should be maintained between the administration of the Next medication. The preparation can be used in pediatric patients (3 years of age and older) at the same dose as in adults. There is no need to change the dosage in elderly patients as well as in patients with impaired renal or hepatic function.
(C)
